Trial Profile

Prospective observational study to evaluate predictive factor for efficacy of Eribulin(KBCSG-TR2018)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 18 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eribulin (Primary) ; Bevacizumab; Capecitabine; Gimeracil/oteracil/tegafur; Paclitaxel
Indications Advanced breast cancer
Focus Biomarker; Therapeutic Use
Acronyms POTENTIAL
Sponsors Eisai Co Ltd

Most Recent Events

10 May 2022 Status changed from recruiting to active, no longer recruiting.
12 Mar 2021 Status changed from not yet recruiting to recruiting.
11 Sep 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com